17 min
IgAN: Current and future therapies | With Prof. Rosanna Coppo Nephrology Knowledge into Practice Podcast
-
- Medicine
Current standard of care for IgA nephropathy (IgAN) involves optimized supportive care, antihypertensives, and dietary and lifestyle modifications. Despite these interventions, ~30% of patients progress to end stage renal disease. Recent approvals of delayed-release budesonide for IgAN and dapagliflozin for chronic kidney disease, and further investigational agents have the potential to alter the treatment landscape for IgAN.
In this episode, Professor Rosanna Coppo offers her expert insight into the potential clinical implications of current and investigational therapies, both now and in the future.
By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.
References:
References available here
This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.
Disclosures:
Prof. Rosanna Coppo has no disclosures to declare.
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Discussion of Off-Label, Investigational or Experimental Drug Use: Atrasentan, C5 inhibitor RNA therapies, eculizumab, empagliflozin, iptacopan, narsoplimab, ravulizumab, and sparsentan are mentioned in the context of the treatment of IgA nephropathy and reducing kidney function decline or failure. Sparsentan is also discussed in the context of the treatment of focal segmental glomerulosclerosis.
Funding:
This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.
Current standard of care for IgA nephropathy (IgAN) involves optimized supportive care, antihypertensives, and dietary and lifestyle modifications. Despite these interventions, ~30% of patients progress to end stage renal disease. Recent approvals of delayed-release budesonide for IgAN and dapagliflozin for chronic kidney disease, and further investigational agents have the potential to alter the treatment landscape for IgAN.
In this episode, Professor Rosanna Coppo offers her expert insight into the potential clinical implications of current and investigational therapies, both now and in the future.
By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.
References:
References available here
This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.
Disclosures:
Prof. Rosanna Coppo has no disclosures to declare.
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Discussion of Off-Label, Investigational or Experimental Drug Use: Atrasentan, C5 inhibitor RNA therapies, eculizumab, empagliflozin, iptacopan, narsoplimab, ravulizumab, and sparsentan are mentioned in the context of the treatment of IgA nephropathy and reducing kidney function decline or failure. Sparsentan is also discussed in the context of the treatment of focal segmental glomerulosclerosis.
Funding:
This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.
17 min